在CNP类似物赛道，Ascendis的TransCon-CNP率先实现了剂型升级。与Vosoritide不一样的设计是TransCon-CNP被一层保护分子包裹，降低了体内清除影响，延长作用时间，实现每周一次给药。非头对头临床数据显示，TransCon-CNP每年2.29厘米的增高表现也优于Vosoritide。
loop for each post url，更多细节参见WPS下载最新地址
直到Vosoritide的获批，才让ACH治疗迈入一个全新的靶向治疗时代。它是一种C型利钠肽(CNP)类似物，通过结合NPR-B进而降低FGFR3的活性来促进生长。临床结果试验显示：相较于安慰剂，每日皮下注射15 μg/kg的Vosoritide，受试者平均年身高增加了1.57厘米。。Line官方版本下载是该领域的重要参考
A year ago, I was one of those skeptics who was very suspicious of the agentic hype, but I was willing to change my priors in light of new evidence and experiences, which apparently is rare. Generative AI discourse has become too toxic and its discussions always end the same way, so I have been experimenting with touching grass instead, and it is nice. At this point, if I’m not confident that I can please anyone with my use of AI, then I’ll take solace in just pleasing myself. Continue open sourcing my projects, writing blog posts, and let the pieces fall as they may. If you want to follow along or learn when rustlearn releases, you can follow me on Bluesky.
Example: deleting a passkey in Apple Passwords